Tauromustine

Tauromustine is an orally active nitrosourea anticancer agent. Tauromustine has an alkylation effect and can damage the DNA function. Tauromustine has a high therapeutic index, especially in the treatment of Walker 256 rat sarcoma. It is also active against melanoma, breast cancer, pleural mesothelioma and ovarian cancer. Tauromustine is mainly metabolized in the liver, but some of its metabolites also have cytotoxicity[1][2][3].

Product Specifications

CAS Number

[85977-49-7]

UNSPSC

12352211

Target

DNA/RNA Synthesis

Related Pathways

Cell Cycle/DNA Damage

Applications

Cancer-programmed cell death

Field of Research

Cancer

Smiles

O=NN(CCCl)C(NCCS(=O)(N(C)C)=O)=O

Molecular Formula

C7H15ClN4O4S

Molecular Weight

286.74

References & Citations

[1]Gregor A, et al. Phase II study of tauromustine in malignant glioma. Eur J Cancer. 1992;28A (12) :1959-62.|[2]Smyth JF, et al. Two phase III trials of tauromustine (TCNU) in advanced colorectal cancer. Ann Oncol. 1995 Nov;6 (9) :948-9.|[3]Bibby MC, et al. Influence of hydralazine on the pharmacokinetics of tauromustine (TCNU) in mice. Br J Cancer. 1992 Mar;65 (3) :347-50.